Science
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19 – EurekAlert
This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab…
What The Study Did: This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab vs placebo on change in day 11 severe acute respiratory syndrome coronavirus 2 viral load in patients with mild to moderate COVID-19.
Authors: Daniel M. Skovronsky, M.D., Ph.D., of Eli Lilly and Company in Indianapolis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at…
-
Noosa News24 hours agoNew Human Rights Commissioner named – Proctor
-
Noosa News21 hours agoCarina Leagues Club unveils $25m Wynnum waterfront plan with new restaurants and bars
-
Noosa News23 hours agoMcCain Australia issues nationwide recall on 400g packets of cheese and bacon pizza pockets after plastic and metal find
-
Noosa News20 hours agoChristmas Day weather: Extended forecast predicts sun for Perth, Adelaide with showers clearing in Sydney and Melbourne